Baxter International Inc. (BAX)
NYSE · Healthcare · Medical Instruments & Supplies
$24.22+3.11%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $12.5B
- Forward P/E
- 11.9
- Dividend yield
- 0.2%
- 52-week range
- $15.73 – $30.00
- 52-week change
- +2.58%
- EPS (trailing)
- −$1.94
- Analyst rating
- 2.7 Hold
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $11.2B (+5.72%)
- Net income
- −$957M
- Operating margin
- −2.7%
- Diluted EPS
- −$1.87
- Free cash flow
- $332M
From the company’s annual report on SEC EDGAR.
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision.
Headquarters: Deerfield, United States · 37,500 employees · baxter.com